<bill session="116" type="h" number="863" updated="2022-11-01T15:17:48Z">
  <state datetime="2019-01-30">REFERRED</state>
  <status>
    <introduced datetime="2019-01-30"/>
  </status>
  <introduced datetime="2019-01-30"/>
  <titles>
    <title type="display">DXM Abuse Prevention Act of 2019</title>
    <title type="short" as="introduced">DXM Abuse Prevention Act of 2019</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to prevent the abuse of dextromethorphan, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="M001163"/>
  <cosponsors>
    <cosponsor bioguide_id="C001067" joined="2019-02-06"/>
    <cosponsor bioguide_id="J000292" joined="2019-01-30"/>
    <cosponsor bioguide_id="K000188" joined="2019-02-07"/>
  </cosponsors>
  <actions>
    <action datetime="2019-01-30">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-01-30" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Child health"/>
    <term name="Civil actions and liability"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
    <term name="Retail and wholesale trades"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-10T14:29:07Z" status="Introduced in House">DXM Abuse Prevention Act of 2019 

This bill addresses the sale and distribution of dextromethorphan (DXM).

Specifically, the bill requires a retailer that sells&#160;certain drugs containing DXM to have a verification system that is&#160;intended to ensure that no one under 18 years of age purchases such drugs from the retailer.

The bill also establishes restrictions on (1)the sale of over-the-counter drugs containing DXM, and (2)the distribution of bulk DXM.</summary>
</bill>
